Literature DB >> 3691609

Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.

P Miskolczi1, L Vereczkey, L Szalay, C Göndöc.   

Abstract

The pharmacokinetics of vinpocetine and its main metabolite, apovincaminic acid (AVA), were studied in the aged. Vinpocetine was eliminated with a mean half-life of 2.12 +/- 0.51 h. Total plasma clearance (CL) and distribution coefficient (delta) of the parent drug were 2.2 +/- 0.9 l.kg-1.h-1 and 6.7 +/- 3.7 l.kg-1, respectively. The CL and delta of vinpocetine differed significantly from young subjects but the elimination half-life was not altered. Significant changes in the elimination half-life and plasma clearance of AVA were found, perhaps because of the physiological decrease in renal function.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3691609     DOI： 10.1007/bf00544565

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  9 in total

1.  General and cerebral haemodynamic activity of ethyl apovincaminate.

Authors:  E Kárpáti; L Szporny
Journal:  Arzneimittelforschung       Date:  1976

2.  Protective activity of ethyl apovincaminate on ischaemic anoxia of the brain.

Authors:  K Biró; E Kárpáti; L Szporny
Journal:  Arzneimittelforschung       Date:  1976

3.  Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency.

Authors:  D Hadjiev; S Yancheva
Journal:  Arzneimittelforschung       Date:  1976

4.  Effect of ethyl apovincaminate on cerebral circulation of dogs under normal conditions and in arterial hypoxia.

Authors:  P Bencsáth; L Debreczeni; L Takács
Journal:  Arzneimittelforschung       Date:  1976

5.  Radiocirculographic study of the effect of ethyl apovincaminate on the cerebral circulation.

Authors:  S Fényes; J Földes
Journal:  Arzneimittelforschung       Date:  1976

6.  Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion.

Authors:  M Polgár; L Vereczkey; I Nyáry
Journal:  J Pharm Biomed Anal       Date:  1985       Impact factor: 3.935

7.  Pharmacokinetics of vinpocetine in humans.

Authors:  L Vereczkey; G Czira; J Tamás; Z Szentirmay; Z Botár; L Szporny
Journal:  Arzneimittelforschung       Date:  1979

8.  Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function.

Authors:  P Miskolczi; L Vereczkey; L Szalay; C S Göndöcs
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

9.  Determination of apovincaminic acid in human plasma by gas-liquid chromatography.

Authors:  M Polgár; L Vereczkey
Journal:  J Chromatogr       Date:  1982-05-28
  9 in total
  7 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.

Authors:  P Miskolczi; K Kozma; M Polgár; L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

3.  Enhanced oral bioavailability of vinpocetine through mechanochemical salt formation: physico-chemical characterization and in vivo studies.

Authors:  Dritan Hasa; Dario Voinovich; Beatrice Perissutti; Mario Grassi; Alois Bonifacio; Valter Sergo; Cinzia Cepek; Michele R Chierotti; Roberto Gobetto; Stefano Dall'Acqua; Sergio Invernizzi
Journal:  Pharm Res       Date:  2011-03-19       Impact factor: 4.200

4.  Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.

Authors:  Csaba Nyakas; Klára Felszeghy; Róbert Szabó; Jan N Keijser; Paul G M Luiten; Zsolt Szombathelyi; Károly Tihanyi
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

5.  Cubosomes with surface cross-linked chitosan exhibit sustained release and bioavailability enhancement for vinpocetine.

Authors:  Yuanfeng Wei; Jianjun Zhang; Yazhen Zheng; Yaxiang Gong; Meng Fu; Chengran Liu; Liang Xu; Changquan Calvin Sun; Yuan Gao; Shuai Qian
Journal:  RSC Adv       Date:  2019-02-21       Impact factor: 4.036

6.  Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice.

Authors:  Jianhui Zhuang; Wenhui Peng; Hailing Li; Yuyan Lu; Ke Wang; Fan Fan; Shuang Li; Yawei Xu
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

7.  Updates of Recent Vinpocetine Research in Treating Cardiovascular Diseases.

Authors:  Chongyang Zhang; Chen Yan
Journal:  J Cell Immunol       Date:  2020
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.